Navarra

我们是谁

  • 1 月 9, 2024
    Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
  • 12 月 8, 2022
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
  • 5 月 23, 2022
    索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤(KRAS)p.G12C 突变患者(代码 300)
  • 4 月 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Repotrectinib(TPX-0005)对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors